Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR T cells for the treatment of cancer patients, and a platform for for the development of gene therapies in other therapeutic indications. Thanks to its fully in-house production capabilities, Cellectis S.A. is one of the few genome-editing companies to control the cell and gene therapy value chain from end to end.

Employees

227

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/26/17	€2.310	-2.37%	81,219
16/26/16	€2.366	-2.79%	2,36,172
15/26/15	€2.434	-4.17%	1,61,937
14/26/14	€2.540	-0.08%	1,18,363
13/26/13	€2.542	-1.85%	81,312

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.310EUR

Average target price

6.500EUR

Spread / Average Target

+181.39%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 09:25:00 17/07/2026 pm IST			5-day change	1st Jan Change
2.310 ^EUR	-2.37%		-10.81%	-44.93%

08/07	European Equities Traded in the US as American Depositary Receipts Decline Sharply in Wednesday Trading	MT
02/07	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading	MT

Market Cap	17Cr 19Cr 15Cr 14Cr 27Cr 1.85TCr 27Cr 184.98Cr 73Cr 905.14Cr 72Cr 70Cr 3.12TCr	P/E 2026 *	-3.04x	P/E 2027 *	-2.03x
Enterprise Value	19Cr 22Cr 17Cr 16Cr 30Cr 2.08TCr 31Cr 207.95Cr 82Cr 1.02TCr 81Cr 79Cr 3.5TCr	EV / Sales 2026 *	3.77x	EV / Sales 2027 *	2.18x
Free-Float	37.35%	Yield 2026 *	-	Yield 2027 *	-

08/07	European Equities Traded in the US as American Depositary Receipts Decline Sharply in Wednesday Trading	MT
02/07	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading	MT
30/06	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT
29/06	European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading	MT
25/06	European Equities Traded in US as ADRs Rise in Thursday Trading	MT
24/06	European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	MT
22/06	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
18/06	European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading	MT
16/06	European Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading	MT
11/06	Cellectis Says Phase 1 Lasme-cel Study Shows 100% Response Rate in B-Cell Leukemia Patients	MT
11/06	Cellectis S.A. Presents Final Phase 1 Results of Lasme-Cel and Preliminary Results on Eti-Cel At Eha 2026 Congress	CI
11/06	Cellectis unveils Phase 1 clinical data
10/06	European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	MT

03/11	Cellectis to Present A Development Update for Eti-Cel At ASH 2025	CI
12/24/12	Oppenheimer Trims Cellectis Price Target to $10 From $11, Maintains Outperform Rating	MT
05/23/05	Citigroup Adjusts Cellectis Price Target to $16 From $24, Maintains Buy Rating	MT
13/23/13	Oppenheimer Adjusts Cellectis Price Target to $13 From $16, Maintains Outperform Rating	MT
24/22/24	Goldman Sachs Adjusts Cellectis' Price Target to $2 from $3, Keeps Sell Rating	MT

Cellectis S.A. Share Price

Stocks

ALCLS

FR0010425595

Biotechnology & Medical Research

Valuation: Cellectis S.A.

Chart: Cellectis S.A.

Latest news : Cellectis S.A.

Last Transcript: Cellectis S.A.

Analysts' recommendations: Cellectis S.A.

Press Releases: Cellectis S.A.

News in other languages: Cellectis S.A.

Quotes and Performance

Course Extremes

Managers and Directors: Cellectis S.A.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

16/07	Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, As Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio	AQ
26/06	Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026	GL
11/06	Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress	GL
10/06	Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL	GL
29/05	Cellectis S A : Report of the Board of Directors - Combined General Meeting of Shareholders - June 25, 2026	PU

26/06	Résultats de l’Assemblée Générale Mixte de Cellectis du 25 juin 2026
19/06	Agenda des dividendes et des AG de la semaine : session dividendes pour la galaxie Bolloré
11/06	Cellectis dévoile les résultats finaux de phase 1 pour lasmé-cel et des données préliminaires pour éti-cel à l'EHA 2026
11/06	Cellectis dévoile des résultats de phase 1
11/06	Bourse : J-1 avant SpaceX, Oracle à la peine, contrat pour Airbus

1 day	-2.37%
1 week	-10.81%
Current month	-10.60%
1 month	-14.32%
3 months	-38.92%
6 months	-33.81%
Current year	-44.93%

1 week	2.29	2.64
1 month	2.29	2.96
Current year	2.29	4.35
1 year	1.49	4.84
3 years	0.89	4.84
5 years	0.89	13.22
10 years	0.89	30

Manager	Title	Age	Since
André Choulika CEO	Chief Executive Officer	61	20/12/1999
David Sourdive COO	Chief Operating Officer	59	01/01/2000
Arthur Stril DFI	Director of Finance/CFO	37	02/05/2024

Director	Title	Age	Since
David Sourdive BRD	Director/Board Member	59	01/01/2000
Laurent Arthaud BRD	Director/Board Member	63	28/10/2011
André Choulika CHM	Chairman	61	01/01/2011

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/06/26	David Sourdive	Sell	Founder	-5,875	0.0081%
29/05/26	André Choulika	Sell	Founder	-5,00,000	0.6913%
29/05/26	David Sourdive	Sell	Founder	-32,042	0.0443%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELLECTIS S.A.	-2.37%	-10.81%	+47.32%	+13.57%	19Cr
LONZA GROUP AG	-1.29%	-3.11%	-0.35%	+3.09%	4.92TCr
REVOLUTION MEDICINES, INC.	+3.90%	-0.39%	+386.06%	+593.85%	3.96TCr
BEONE MEDICINES AG	-1.70%	+4.46%	+5.93%	+60.25%	3.47TCr
IQVIA HOLDINGS INC.	-2.01%	-0.76%	+28.41%	-8.01%	3.44TCr
CELLTRION, INC.	+0.06%	+0.34%	+2.38%	+34.38%	2.71TCr
ASCENDIS PHARMA A/S	+0.46%	-3.49%	-	-	1.62TCr
MEDPACE HOLDINGS, INC.	-0.04%	-0.09%	+72.42%	+115.55%	1.54TCr
EUROFINS SCIENTIFIC SE	+1.12%	+1.91%	+14.54%	+19.16%	1.41TCr
ICON PUBLIC LIMITED COMPANY	0.00%	+1.36%	+18.43%	-30.79%	1.3TCr
Average	-0.19%	-1.06%	+63.90%	+89.00%	2.44TCr
Weighted average by Cap.	-0.06%	-0.19%	+79.42%	+123.22%

	2026 *	2027 *
Net sales	5Cr 5.73Cr 4.62Cr 4.26Cr 8.02Cr 551.37Cr 8.2Cr 55Cr 22Cr 270.04Cr 22Cr 21Cr 929.6Cr	5.73Cr 6.55Cr 5.28Cr 4.87Cr 9.18Cr 630.88Cr 9.38Cr 63Cr 25Cr 308.98Cr 25Cr 24Cr 1.06TCr
Net income	-7.89Cr -9.02Cr -7.28Cr -6.71Cr -13Cr -868.95Cr -13Cr -87Cr -34Cr -425.57Cr -34Cr -33Cr -1.47TCr	-11Cr -13Cr -10Cr -9.47Cr -18Cr -1.23TCr -18Cr -122.76Cr -48Cr -600.7Cr -48Cr -47Cr -2.07TCr
Net Debt	2.08Cr 2.38Cr 1.92Cr 1.77Cr 3.34Cr 229.55Cr 3.41Cr 23Cr 9.04Cr 112.42Cr 8.95Cr 8.76Cr 387.01Cr	-4.28Cr -4.9Cr -3.95Cr -3.64Cr -6.87Cr -472.14Cr -7.02Cr -47Cr -19Cr -231.23Cr -18Cr -18Cr -796.01Cr